Our History
Cancer - a formidable foe
Cancer continues to be a leading cause of death around the world. Despite tremendous progress being made in the development of new therapies, the incidence and prevalence of cancers have steadily risen. Moreover, access to these innovative therapies are at times limited to patients in unmet need due to either resistance to therapies or general cost of access.
Our Mission
Current approaches in immunotherapy are focused on activating or modulating the immune system to eradicate tumors in the tumor micro-environment (TME). While such approaches have become effective therapies for patients, the occurrence of adverse events and toxicities remain a challenge.
In TME cancer cells directly interact with both the immune system and the stroma and in turn the stroma responds with pro-inflammatory and anti-tumor makers. Understanding the cross talk between immune cells, stroma and cancer cells may lead to the discovery of novel pathways and biomarkers.
We aim to interrogate the TME for the stromal-immune-tumor factors to develop novel therapeutics for cancer.
